Small-Molecule Inhibitors for Novel Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 31 January 2025
Special Issue Editors
Interests: neuropharmacology; neuroscience; drug discovery; brain histamine; brain carbonic anhydrases; oxytocin
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; protein inhibition/activation; organic synthesis; enzymology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Small-molecule inhibitors represent a promising frontier in the development of novel therapeutics. These compounds are designed to specifically interact with and inhibit the function of target proteins that play critical roles in disease processes. By binding to these proteins, small-molecule inhibitors can disrupt pathological signaling pathways, offering a strategic approach to treating conditions such as cancer, autoimmune disorders, and infectious diseases. Recent advances in molecular biology and high-throughput screening have enabled the identification of previously undruggable targets, expanding the potential applications of these inhibitors. This Special Issue aims to describe the recent developments of small molecules with a focus on enhancing their specificity, potency, safety profiles, and drug delivery toward novel therapeutic targets. Original research articles and reviews are welcome.
We look forward to receiving your contributions.
Dr. Gustavo Provensi
Dr. Simone Giovannuzzi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- small molecules
- enzyme inhibition/activation
- protein modulation
- novel therapeutics
- high-throughput screening
- target proteins
- drug delivery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
